Asset Lead Medical Director - Obesity and Related Conditions

Join Amgen’s Mission of Serving Patients

At Amgen, if you feel like you’re part of something bigger, it’s because you are. Our shared mission—to serve patients living with serious illnesses—drives all that we do.

Since 1980, we’ve helped pioneer the world of biotech in our fight against the world’s toughest diseases. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat heart disease, obesity and obesity-related conditions, rare diseases, inflammatory conditions and cancer. As a member of the Amgen team, you’ll help make a lasting impact on the lives of patients as we research, manufacture, and deliver innovative medicines to help people live longer, fuller happier lives.

Our award-winning culture is collaborative, innovative, and science based. If you have a passion for challenges and the opportunities that lay within them, you’ll thrive as part of the Amgen team. Join us and transform the lives of patients while transforming your career.

Asset Medical Lead Medical Director – Cardiovascular & Metabolic (CVM) Strategy

What you will do

Let’s do this. Let’s change the world. In this vital role, you will lead the development and delivery of U.S. Cardiovascular & Metabolic (CVM) Medical strategy for maridebart cafraglutide (also known as MariTide), an investigational therapy developed by Amgen and being studied for obesity and obesity-related conditions. You will establish the cross-indication scientific, evidence, stakeholder, and implementation foundation that supports chronic weight management (CWM) launch readiness and prepares the organization for maturation in CVM. In partnership with the U.S. Medical Portfolio Lead, TA Head, Global Medical, and cross-functional colleagues, you will translate global strategy into an integrated U.S. Medical plan.

Responsibilities

• Lead U.S. CVM Medical strategy, with initial emphasis on CWM launch support and early CV readiness.
• Build an integrated, evidence-based CVM narrative linking obesity and the broader care continuum.
• Define U.S. scientific evidence gaps and shape local evidence, RWE, HEOR, and Access and Use Evidence Generation priorities in alignment with global plans.
• Synthesize customer, field, market, and medical insights to inform U.S. Medical, Brand, evidence, and implementation decisions.
• Develop the early external-engagement plan for cardiologists, HF specialists, integrated delivery networks, professional societies, payers, and other priority stakeholders.
• Partner with Global Medical, Global Development, CfOR, HEOR, Medical Value and Access, and Scientific Communications to translate emerging evidence into U.S. strategy and execution.
• Lead or support U.S. scientific communications, including the scientific platform, core content, publication implementation, congress plans, and medical education.
• Support clinical trial activities and data interpretation as a U.S. Medical interface with Global Clinical Development and evidence-generation teams.
• Lead or support advisory boards, expert panels, and implementation-science initiatives that clarify real-world care pathways, referral patterns, and barriers to appropriate care.
• Provide medical input into reimbursement, policy, regulatory, label, and promotional-material discussions consistent with governance and evidence.
• Serve as a medical representative in leadership, governance, launch-readiness, and cross-functional teams; recommend priorities and resource trade-offs for the U.S. Medical plan.